Powl Brian T. - 02 Jan 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Commercial Officer
Signature
Teresa Bair, Attorney-in-fact for Brian Powl
Issuer symbol
KURA
Transactions as of
02 Jan 2025
Net transactions value
$0
Form type
4
Filing time
06 Jan 2025, 16:07:04 UTC
Previous filing
04 Jan 2024
Next filing
28 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +46,250 +308% $0.000000 61,250 02 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KURA Option to purchase common stock Award $0 +92,500 $0.000000 92,500 02 Jan 2025 Common Stock 92,500 $8.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/26, 1/26/27, 1/26/28 and 1/26/29.
F2 This option vests in 48 equal monthly installments commencing on the grant date.